Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

CLICK HERE FOR CME CREDIT

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR